H.I.G. Is Said to Consider Sale of $1 Billion Drugmaker Rising Pharma

Summary

H.I.G. Capital is considering a sale of its controlling stake in Rising Pharmaceuticals, a US-based drugmaker valued at $1 billion. The potential transaction could involve divesting the stake through a sale process, which may attract interest from private equity firms or strategic buyers.

Market Context

The article does not provide direct evidence of market impact, but a sale process for Rising Pharmaceuticals could affect valuation multiples for mid-sized pharmaceutical companies or private equity-owned drugmakers, potentially influencing peers like Perrigo (PRGO) or Endo International (ENDO) through sector comparables.

Key Drivers

• H.I.G. Capital's exploration of a sale for Rising Pharmaceuticals
• Potential transaction involving a $1 billion valuation
• Private equity divestiture process in the pharmaceutical sector

Risks

• No details on buyer interest, timeline, or execution certainty
• Article does not specify whether the sale would be to a strategic or financial buyer
• Valuation of $1 billion is not independently verified

Time Horizon

Medium Term